A pattern I see consistently in clinical work with women in midlife: she has been in treatment for depression or anxiety for several years. The treatment has helped, partially. She is managing. But something doesn't fully resolve, and neither she nor her previous clinicians have connected her symptoms to the stage she is in.
She is 44, or 47, or 51. She is in perimenopause. And nobody has asked about that.
This is not an unusual presentation. It is, in my experience, a common one. The mental health burden of the perimenopausal transition is one of the most robustly documented and least communicated findings in women's health research. Women arrive in clinical rooms carrying symptoms that are predictable, biologically anchored, and often treatable - and they arrive having assumed for years that something was personally wrong with them.
The numbers that matter
Research consistently shows that women in perimenopause face a 40% increased risk of depression compared to premenopausal women. Women aged 40-49 report feeling hopeless at 40% higher levels than women over 50. This is not a small signal. It is a pattern that concentrates specifically in the transition period - the years of hormonal fluctuation before menopause is complete - rather than after.
The SWAN study, one of the most important longitudinal studies of women's health across the menopausal transition, followed over 3,000 women for more than a decade. It found that the menopausal transition itself conferred independent risk for depression - independent of life stress, socioeconomic factors, and baseline mood history. The perimenopausal period was the highest-risk window.
One finding from SWAN's thirteen-year follow-up stands out in particular: women with any prior history of depression - even a single episode, even decades ago - have a 59% rate of experiencing another depressive episode during perimenopause. The rate for women without that history is 28%. That gap is clinically significant. And it is almost never communicated to women in advance.
Why it is not just hormones
The hormonal dimension of perimenopausal mood disturbance is real and important. Estrogen modulates serotonin, dopamine, and GABA systems directly. Erratic fluctuations in estrogen during perimenopause - which can begin years before the final menstrual period - repeatedly destabilise these neurotransmitter systems. The result is not simply low mood. It can include anxiety that feels physical and unexplained, irritability that arrives disproportionately, cognitive fog, sleep disruption, and a pervasive sense that something is fundamentally wrong without a clear reason.
But hormones alone do not fully explain the pattern. Research consistently identifies prior mental health history, adverse childhood experiences, and current psychological stress load as stronger predictors of perimenopausal mood disturbance than hormone levels alone.
This is a finding worth sitting with. It means that perimenopause is not simply a hormonal event that produces mood symptoms in vulnerable biology. It is a period in which the biology amplifies what is already psychologically unresolved. Women who carry histories of trauma, chronic invalidation, or relational difficulty - and who have managed these through the strategies that midlife eventually makes unsustainable - are at particular risk during this window.
The biological changes do not create the psychological material. They remove some of the buffering capacity that kept it manageable.
What gets missed in treatment
The clinical implications of this are significant. Many women presenting with depression or anxiety in their forties are prescribed antidepressants without the hormonal context being considered. Sometimes this is appropriate - SSRIs and SNRIs have demonstrated efficacy for perimenopausal mood symptoms, and for moderate to severe depressive disorder they remain a primary treatment option. The issue is not antidepressants themselves. It is reflexive prescription that treats one layer without attending to the others.
The FIGO 2025 international guidelines on mental health during the menopausal transition - representing clinical consensus across 130 countries - are now explicit on this point. They identify transdermal estradiol as a first-line treatment option for mood symptoms during the perimenopausal transition, particularly in women with metabolic risk. They call for proactive mental health screening to become standard at every midlife consultation. They name the risk window clearly.
What this means practically is that a woman with a prior history of depression who presents to her GP in her mid-forties with mood symptoms should not simply be offered the same antidepressant she took before. The hormonal biology should be part of the clinical conversation. The psychological and relational context should be part of the clinical conversation. Treatment that addresses only one of these layers provides incomplete relief - and leaves the woman believing the problem is more intractable than it actually is.
What adequate support looks like
Adequate support for perimenopausal mental health is integrated. It considers the neurobiological component - whether hormonal stabilisation is appropriate and, if so, in what form. It considers the psychological component - what the perimenopausal transition is surfacing in terms of identity, relationships, and unprocessed experience. And it holds both without collapsing one into the other.
For many women, perimenopause is the first time the psychological material they have been managing through competence, over-functioning, and emotional containment becomes impossible to maintain at the same level. The reduction in the brain's buffering capacity means that what was contained begins to surface. This is not breakdown. But it does require a different kind of attention than "take this and come back in six weeks."
It also requires time. The perimenopausal transition is not a brief event. For many women it spans five to ten years. Treatment that expects rapid resolution of a multi-year neurobiological and psychological process will consistently disappoint. The frame matters: this is a transition, not a crisis to be eliminated.
The silence around it
What I find most significant, after years of working with women in this window, is not the severity of what they experience. It is the silence they experienced before arriving in a clinical room. They had spent years interpreting their symptoms as personal inadequacy. They assumed the depression returning meant they hadn't worked hard enough in previous therapy, or that they were fundamentally more fragile than they had believed. They had not been told that this was a predictable window, that their history made them statistically more vulnerable, that there was both a biological and a psychological component to address.
That silence has a cost. It compounds the symptoms with shame. And shame, in my clinical experience, is one of the most reliable ways to keep someone from seeking appropriate help.
The research exists. The clinical guidelines have shifted. What is still lagging is the transmission of that information to the women who need it - before the window opens, not after they have spent years inside it without a map.